Purging peripheral blood progenitor cell grafts from lymphoma cells: Quantitative comparison of immunomagnetic CD34+ selection systems

Stem Cells

Volumn 15, Issue 4, 1997, Pages 297-304

  Paulus, Ulrike ^a,b   Dreger, Peter ^a   Viehmann, Karin ^a   Von Neuhoff, Nils ^a   Schmitz, Norbert ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Second Department of Medicine   (Germany)

Author keywords

CD34+ selection; Lymphoma; PBPC; PCR; Purging

Indexed keywords

CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL MOTILITY; CELL SELECTION; CELL SEPARATION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE MICROSCOPY; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION;

EID: 0030812441     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150297     Document Type: Article

References (33)

1. Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987;316:1499-1505.
2. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 1991;77:2524-2529.
3. Rohatiner AZS, Johnson PWM, Price CGA et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994;12:1177-1184.
4. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994;12:1685-1692.
5. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257-3262.
6. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-357.
7. Sharp JG, Kessinger A, Vaughan WP et al. Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Cloning 1992;10:92-95.
8. Hardingham JE, Kotasek D, Sage RE et al. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 1993;11:15-20.
9. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-1533.
10. Dreger P, Neuhoff NV, Suttorp M et al. Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immunomagnetic beads. Bone Marrow Transplant 1995;16:627-629.
11. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
12. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995;86:390-397.
13. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995;85:1647-1654.
14. Dreger P, Klöss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3974-3978.
15. Lok M-S, Koshiba H, Han T et al. Establishment and characterization of human B-lymphocytic lymphoma cell lines (BALM-3, -4 and -5): intraclonal variation in the B-cell differentiation stage. Int J Cancer 1979;24:572-578.
16. Dyer MJS, Fischer P, Nacheva E et al. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4; 11 ) chromosomal translocations. Blood 1990;75:709-714.
17. Reynolds CP, Seeger RC, Vo DD et al. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986;46:5882-5886.
18. + selection systems or CAMPATH-1. Exp Hematol 1995;23:147-154.
19. + cell determination by flow cytometry. J Hematother 1996;5:213-226.
20. Strijbosch LWG, Does RJMM, Buurman WA. Computer-aided design and evaluation of limiting and serial dilution experiments. Int J Biomed Comput 1988;23:279-283.
21. Brenner MK, Rill DR. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother 1994;3:33-36.
22. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995;85:275-282.
23. + blood cells. Blood 1996;87:4903-4909.
24. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
25. + cells: a short review of the immunoadsorption methods currently available for experimental and clinical use. J Hematother 1993;2:473-481.
26. + cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems. STEM CELLS 1995;13:524-532.
27. + progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. Blood 1995;86:4691-4698.
28. Brugger W, Heimfeld S, Berenson RJ et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283-287.
29. - lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins. Bone Marrow Transplant 1994;13:465-471.
30. + PBPC selected with the Isolex300 system. Exp Hematol 1996;24:1150.
31. + cells isolated with the Amgen Cell Selector provide rapid engraftment following high dose chemotherapy in breast cancer patients. Blood 1996;88:110a.
32. + cells using the Amgen cell selection device results in high levels of purity and recovery. J Hematother 1997;6:5-11.
33. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995;85:1647-1654.